Search results for " Lymphatic"

showing 10 items of 854 documents

Allogeneic Stem Cell Transplant Versus Tandem High-Dose Melphalan for Front-Line Treatment of Deletion 13q14 Myeloma – An Interim Analysis of the Ger…

2009

Abstract Abstract 51 Background Allogeneic stem cell transplantation (allo SCT), a treatment modality based on transfer of immunocompetent donor lymphocytes offers curative potential to subjects with a variety of hematological cancers. In multiple myeloma (MM), high-dose melphalan followed by autologous stem cell transplantation (auto SCT) is adopted as a standard of care. However, it remains palliative since virtually all patients (pts) relapse and renders allo SCT an option of interest. Deletion of chromosome 13q14 (13q-) in MM has been shown to negatively impact prognosis. Therefore, improvement of therapy for 13q- pts is highly desirable. Patients and methods A prospective two-arm multi…

MelphalanOncologymedicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologymedicine.diseaseInterim analysisDonor LymphocytesBiochemistrySurgeryFludarabineTransplantationsurgical procedures operativeAutologous stem-cell transplantationMedian follow-uphemic and lymphatic diseasesInternal medicinemedicinebusinessMultiple myelomamedicine.drugBlood
researchProduct

Sezernierter Interleukin-2-Rezeptor als Aktivitätsparameter der Sarkoidose*

2008

Serum sIL-2-R levels were measured in 28 sarcoidosis patients at multiple time points before, during, and after therapy, with a mean follow-up time of 10.2 +/- 5.2 months, and the results compared with the clinical activity of the disease. Before therapy, 20 out of 24 episodes with active disease exhibited elevated levels of sIL-2-R (918 +/- 362 U/ml). In inactive disease after tapering off corticoid therapy the sIL-2-R levels were 453 +/- 274 U/ml. Disease activity under therapy also correlated with sIL-2-R serum levels. 23 out of 29 episodes with signs of activity under therapy had elevated sIL-2-R levels (808 +/- 409 U/ml). Only three of 28 patients in whom disease activity ceased after …

medicine.medical_specialtybusiness.industryGeneral MedicineDiseasemedicine.diseaseGastroenterologyfemale genital diseases and pregnancy complicationsDisease activityPulmonary sarcoidosisimmune system diseaseshemic and lymphatic diseasesInternal medicineActive diseaseMultiple timeMedicineSarcoidosisbusinessInactive diseaseReceptorDMW - Deutsche Medizinische Wochenschrift
researchProduct

Clinical conditions responsible for hyperviscosity and skin ulcers complications

2017

In this brief review, we have examined some clinical conditions that result to be associated to an altered hemorheological profile and at times accompanied by skin ulcers. This skin condition may be observed in patients with the following condtions, such as primary polycythemic hyperviscosity (polycythemia, thrombocytemia) treated with hydroxyurea, primary plasma hyperviscosity (multiple myeloma, cryoglobulinemia, cryofibrinogenemia, dysfibrinogenemia, and connective tissue diseases), primary sclerocythemic hyperviscosity (hereditary spherocytosis, thalassemia, and sickle cell disease). In addition, it may be present in patients with secondary hyperviscosity conditions such as diabetes mell…

medicine.medical_specialtyPhysiologyChronic venous insufficiencyBlood viscosityHyperviscosity syndromeCryofibrinogenemiaHyperviscosity030204 cardiovascular system & hematologyGastroenterologyHyperviscosity syndrome; blood viscosity; skin ulcers030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineskin ulcershemic and lymphatic diseasesPhysiology (medical)Internal medicineHyperviscosity syndromeSkin UlcermedicineHumansbusiness.industryHematologyCritical limb ischemiaSkin ulcermedicine.diseaseCryoglobulinemiablood viscositymedicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct

Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocy…

2018

Relapse of acute leukemia (AL) after allogeneic hematopoietic cell transplantation (Allo-HCT) entails a dismal prognosis. In this scenario, donor lymphocyte infusions (DLIs) and second Allo-HCT are two major approaches. We compared outcomes of AL patients treated for relapse with DLI or second Allo-HCT after receiving debulking therapy. In total, 46 patients were included in the study; 30 (65%) had acute myeloid leukemia and 16 (35%) had acute lymphoblastic leukemia. The median age was 38 years (range 4-66). Twenty-seven patients received a second Allo-HCT and 19 patients received DLI. The median follow-up of the cohort was 273 days (range 9-7013). Overall survival (OS), disease-free surviv…

OncologyMaleCancer ResearchTransplantation Conditioningmedicine.medical_treatmentSalvage therapyHematopoietic stem cell transplantationKaplan-Meier EstimateCohort Studies0302 clinical medicineRecurrencehemic and lymphatic diseasesCumulative incidenceChildAcute leukemiaUnivariate analysisHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsLeukemiaLeukemia Myeloid Acutesurgical procedures operative030220 oncology & carcinogenesisChild PreschoolLymphocyte TransfusionFemaleLeukocyte Reduction ProceduresAdultmedicine.medical_specialtyAdolescentGraft vs Leukemia EffectDisease-Free Survival03 medical and health sciencesYoung AdultInternal medicineGeneticsmedicineHumansMolecular BiologyAgedRetrospective StudiesImmunosuppression TherapySalvage Therapybusiness.industryCell Biologymedicine.diseaseTransplantationbusiness030215 immunologyExperimental hematology
researchProduct

Fever of Unclear Origin and Cytopenia Because of Acute Splenic Sequestration in a Young Immunocompetent Carrier of Beta-Globin Mutation for Hb Vallet…

2008

Fever of unclear origin is a clinical challenge in medical practice. Infectious diseases, neoplasms, and collagen vascular illnesses are its main causes in adults and children. Acute splenic sequestration crises, a known potentially fatal complication of sickle cell disease and sickle beta-thalassemia, are uncommon in beta-heterozygosis. We describe a case of prolonged recurrent episodes of fever with spontaneous resolution, commencing at age 10 in a 15-year-old boy with a history of hypochromic microcytic anemia attributed to a thalassemic trait. He was admitted twice to our university hospital for continuous-remittent fever with a pruritic, macular evanescent Still's skin rash, severe spl…

AdultMaleAdolescentFeverAnemiaHemoglobins AbnormalThalassemiaHepatosplenomegalybeta-Globinshemic and lymphatic diseasesmedicineHumansChildCytopeniabusiness.industryBeta thalassemiaAnemiaGeneral Medicinemedicine.diseaseHematologic DiseasesHypochromic microcytic anemiaHemoglobinopathyMutationImmunologymedicine.symptomSplenic diseasebusinessImmunocompetenceSpleenThe American Journal of the Medical Sciences
researchProduct

Gut microbiota regulate hepatic von Willebrand factor synthesis and arterial thrombus formation via Toll-like receptor-2.

2016

The symbiotic gut microbiota play pivotal roles in host physiology and the development of cardiovascular diseases, but the microbiota-triggered pattern recognition signaling mechanisms that impact thrombosis are poorly defined. In this article, we show that germ-free (GF) and Toll-like receptor-2 (Tlr2)-deficient mice have reduced thrombus growth after carotid artery injury relative to conventionally raised controls. GF Tlr2-/- and wild-type (WT) mice were indistinguishable, but colonization with microbiota restored a significant difference in thrombus growth between the genotypes. We identify reduced plasma levels of von Willebrand factor (VWF) and reduced VWF synthesis, specifically in he…

0301 basic medicineBlood Plateletsmedicine.medical_specialtyEndotheliumPlatelet AggregationImmunologyBiologyBiochemistry03 medical and health sciencesMiceVon Willebrand factorhemic and lymphatic diseasesInternal medicinevon Willebrand FactormedicineAnimalsGerm-Free LifePlateletThrombusIntegrin bindingMice KnockoutToll-like receptorThrombosisCell BiologyHematologymedicine.diseaseToll-Like Receptor 2Gastrointestinal MicrobiomeTLR2030104 developmental biologymedicine.anatomical_structureEndocrinologyLivercardiovascular systembiology.proteinSignal transductioncirculatory and respiratory physiologySignal TransductionBlood
researchProduct

AN IL-6/IL-6 SOLUBLE RECEPTOR (IL-6R) HYBRID PROTEIN (H-IL-6) INDUCES EPO-INDEPENDENT ERYTHROID DIFFERENTIATION IN HUMAN CD34+CELLS

2000

H-IL-6 is a hybrid protein constructed to contain IL-6 and its soluble receptor linked by a flexible peptide chain. Here we show that H-IL-6 strongly enhances proliferation of human CD34(+)cells in serum-free liquid culture, and that the majority of the cells generated belong to the erythroid lineage, being positive for the marker Glycophorin A. Conversely, H-IL-6 does not increase the number of myeloid, CD13-positive cells. Comparable effects are observed on progenitors from cord blood and adult peripheral blood. Therefore, H-IL-6 triggers an erythroid-inducing signal in haematopoietic progenitor cells, independently from erythropoietin (EPO).

ErythrocytesTime FactorsMyeloidCellular differentiationInterleukin 6Antigens CD34BiochemistryCulture Media Serum-FreeSerum-Freehemic and lymphatic diseasesReceptorsLeukocytesImmunology and AllergyErythropoiesisGlycophorinsStem Cell FactorbiologyChemistryCord bloodCell DifferentiationHematologyFetal BloodFlow CytometryEndothelial stem cellHaematopoiesismedicine.anatomical_structureGlycophorinCD34+medicine.drugRecombinant Fusion ProteinsMononuclearImmunologyCD13 AntigensmedicineHumansGlycophorinAntigensProgenitor cellErythropoietinMolecular BiologyInterleukin 3Interleukin-6CD34+; Cord blood; Erythropoiesis; Interleukin 6; Stem cell factor; Antigens CD34; CD13 Antigens; Cell Differentiation; Culture Media Serum-Free; Erythrocytes; Erythropoietin; Fetal Blood; Flow Cytometry; Glycophorin; Hematopoietic Stem Cells; Humans; Interleukin-6; Leukocytes Mononuclear; Peptides; Receptors Interleukin-6; Recombinant Fusion Proteins; Stem Cell Factor; Time Factors; Immunology and Allergy; Immunology; Biochemistry; Hematology; Molecular BiologyHematopoietic Stem CellsReceptors Interleukin-6Molecular biologyCulture MediaErythropoietinLeukocytes Mononuclearbiology.proteinCD34PeptidesCytokine
researchProduct

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells

2018

CD38 is overexpressed by multiple myeloma cells and has emerged as a target for therapeutic antibodies. Nanobodies are soluble single domain antibody fragments derived from the VHH variable domain of heavy chain antibodies naturally occurring in camelids. We previously identified distinct llama nanobodies that recognize three non-overlapping epitopes of the extracellular domain of CD38. Here, we fused these VHH domains to the hinge, CH2, and CH3 domains of human IgG1, yielding highly soluble chimeric llama/human heavy chain antibodies (hcAbs). We analyzed the capacity of these hcAbs to mediate complement-dependent cytotoxicity (CDC) to CD38-expressing human multiple myeloma and Burkitt lymp…

0301 basic medicinelcsh:Immunologic diseases. AllergyRecombinant Fusion ProteinsImmunologyAntineoplastic AgentsEpitope03 medical and health sciencesbiparatopic antibodiesAntigens Neoplasmhemic and lymphatic diseasesCell Line TumorAntibodies BispecificImmunology and AllergyAnimalsHumansCytotoxicitycomplement-dependent cytotoxicityOriginal ResearchHeavy-chain antibodybiologyheavy chain antibodyantibody engineeringChemistryAntibody-Dependent Cell CytotoxicityDaratumumabAntibodies MonoclonalComplement System ProteinsSingle-Domain AntibodiesADP-ribosyl Cyclase 1Complement-dependent cytotoxicityCell biologymultiple myelomananobody030104 developmental biologySingle-domain antibodyCell culturebiology.proteinEpitopes B-LymphocyteImmunotherapyAntibodylcsh:RC581-607Immunoglobulin Heavy ChainsCamelids New WorldCD38Frontiers in Immunology
researchProduct

STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.

2012

Abstract MOZ-TIF2 is a leukemogenic fusion oncoprotein that confers self-renewal capability to hematopoietic progenitor cells and induces acute myelogenous leukemia (AML) with long latency in bone marrow transplantation assays. Here, we report that FLT3-ITD transforms hematopoietic cells in cooperation with MOZ-TIF2 in vitro and in vivo. Coexpression of FLT3-ITD confers growth factor independent survival/proliferation, shortens disease latency, and results in an increase in the number of leukemic stem cells (LSC). We show that STAT5, a major effector of aberrant FLT3-ITD signal transduction, is both necessary and sufficient for this cooperative effect. In addition, STAT5 signaling is essent…

Cancer ResearchMyeloidOncogene Proteins Fusionmedicine.medical_treatmentArticleMyelogenousMicehemic and lymphatic diseasesmedicineSTAT5 Transcription FactorAnimalsSTAT5Mice Inbred BALB CbiologyGrowth factormedicine.diseaseFlow CytometryHaematopoiesisLeukemiaBlotting SouthernLeukemia Myeloid Acutemedicine.anatomical_structureCell Transformation NeoplasticOncologyCancer researchbiology.proteinNeoplastic Stem CellsSignal transductionStem cellSignal TransductionCancer research
researchProduct

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

2011

Abstract Marginal zone B-cell lymphomas (MZLs) have been divided into 3 distinct subtypes (extranodal MZLs of mucosa-associated lymphoid tissue [MALT] type, nodal MZLs, and splenic MZLs). Nevertheless, the relationship between the subtypes is still unclear. We performed a comprehensive analysis of genomic DNA copy number changes in a very large series of MZL cases with the aim of addressing this question. Samples from 218 MZL patients (25 nodal, 57 MALT, 134 splenic, and 2 not better specified MZLs) were analyzed with the Affymetrix Human Mapping 250K SNP arrays, and the data combined with matched gene expression in 33 of 218 cases. MALT lymphoma presented significantly more frequently gain…

MalePathologyLymphomaMarginal ZoneBiochemistryExtranodal Diseaseclassification/genetics/pathologyhemic and lymphatic diseases80 and overgeneticsAged 80 and overComparative Genomic HybridizationGenomeMALT lymphomaHematologySingle NucleotideMiddle AgedMarginal zonePrognosisGene Expression Regulation NeoplasticAdult Aged Aged; 80 and over Chromosome Aberrations Comparative Genomic Hybridization DNA Fingerprinting Female Gene Expression Profiling Gene Expression Regulation; Neoplastic Genome; Human Humans Lymphoma; B-Cell; Marginal Zone; classification/genetics/pathology Male Middle Aged Polymorphism; Single Nucleotide; genetics Prognosis Splenic Neoplasms; classification/genetics/pathology Young AdultFemaleHumanAdultmedicine.medical_specialtyGenome-wide DNA profilingImmunologyBiologyPolymorphism Single NucleotideYoung AdultGenome-wide DNA profiling; marginal zone lymphomas; clinical outcome.medicineSNPHumansSplenic marginal zone lymphomaPolymorphismAgedChromosome AberrationsNeoplasticGenome HumanSplenic Marginal Zone Lymphoma; GenomicGene Expression ProfilingSplenic NeoplasmsB-CellLymphoma B-Cell Marginal ZoneCell Biologyclinical outcome.medicine.diseasemarginal zone lymphomaDNA FingerprintingLymphomaGene expression profilingGene Expression RegulationComparative genomic hybridization
researchProduct